Mukka Proteins Limited has scheduled a board meeting on June 12, 2026, to consider and approve a proposal for raising funds by issuing securities. The board will evaluate various instruments, including a preferential issue, rights issue, or any other mode deemed appropriate for the capital raise.

The meeting is being convened in accordance with Regulation 29(1)(d) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The company has not yet specified the exact amount of funds it intends to raise or the specific instrument that will be utilized.

In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the company's securities has been closed for designated persons and their immediate relatives. This restriction is effective from June 9, 2026, and will remain in place until 48 hours after the outcome of the board meeting is declared.

Key Meeting Details

The company secretary, Mehaboobsab Mahmaddous Chalyal, confirmed the intimation to the exchanges.

Mukka Proteins Limited has announced its audited financial results for the quarter and year ended March 31, 2026, reporting strong growth across key metrics. The company achieved a revenue of INR 1,449.5 crore for the full year, a significant increase of 44.0% year-on-year. Profit after tax (PAT) for FY26 stood at INR 57.1 crore, up 18.7% from the previous year, while EBITDA grew 30.9% to INR 145.3 crore. The board approved the financial results at its meeting on May 15, 2026.

Consolidated Performance

Mukka Proteins delivered robust consolidated results for the fourth quarter. Q4 revenue reached INR 380.6 crore, while EBITDA surged 48.0% to INR 49.2 crore. The EBITDA margin expanded by 421 basis points to 12.9%. Q4 PAT rose 52.6% to INR 21.4 crore, with a PAT margin of 5.6%. The company attributed the performance to strong demand, improved pricing, and operational efficiencies.

Fund Raising and Strategic Investments

The board approved raising funds by issuing secured, rated, listed, redeemable non-convertible debentures (NCDs) worth INR 25 crore on a private placement basis via the Electronic Bidding Platform (EBP). Additionally, the board approved raising up to INR 50 crore through NCDs in one or more tranches via EBP or non-EBP. The first tranche of INR 25 crore carries a coupon rate of 12.00% per annum and a tenor of 15 months.

In strategic expansion moves, the board approved incorporating an overseas entity in Sri Lanka, "Lanka Bio Proteins Private Limited", with an investment of up to INR 2.50 crore for a 49% stake. The company also approved an investment of INR 2.55 lakh for a 51% profit-sharing stake in a proposed partnership firm, "MPL FC HRC JV", focused on the treatment and disposal of animal waste.

Strategic Expansion and Sustainability

The company is advancing its sustainable sourcing initiatives through the MarinTrust Improver Programme. To bolster capacity, Mukka Proteins is establishing a new facility in the Aljoubah Industrial Area in Oman, spread over 21,249 sq. mt. The company also secured a contract from BBMP/BSWML for integrated animal waste management in Bengaluru.